Health/Employee Benefits News
Newswires RSS Get our newsletter
Order Prints
Newswires

2024 Annual Report

Company Profile

Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Molina Healthcare served approximately 5.5 million members as of December 31, 2024. For more information about Molina Healthcare, please visit molinahealthcare.com.

Line of Business Profile

Membership by Line of Business

Premium by Line of Business

88%

Medicaid

5%

Marketplace

7%

Medicare

Historical Highlights

Premium Revenue

Diluted GAAP Net

($ Millions)

Income per Share

'20

18,299

'20

$11.23

'21

26,855

'21

$11.25

'22

30,883

'22

$13.55

'23

'23

32,529

$18.77

'24

'24

38,627

$20.42

79%

Medicaid

7%

Marketplace

14%

Medicare

Diluted Adjusted Net

Income per Share

'20

$10.67

'21

$13.54

'22

$17.92

'23

$20.88

'24

$22.65

See the reconciliation of GAAP to Adjusted Net Income per Shareon Page A3

Annual Meeting

The annual meeting of stockholders will be held on Wednesday, April 30, 2025, at 10:00 a.m. EasteTime live via the internet at www.virtualshareholdermeeting.com/MOH2025.

To Our Stockholders:

We are pleased to report that we continued to deliver strong results for all our stakeholders this year, producing pre-tax income margins within our long-term target range while effectively growing premium revenue.

Our management team and our nearly 18,500 associates worked tirelessly in our mission to improve the health and lives of the 5.5 million members we serve by delivering high quality, affordable healthcare. Their commitment is unwavering and drives successes across the enterprise, from serving our existing members, to growing business in existing states, winning new business in new states, and integrating our recently acquired health plans.

We continue to execute our strategy for sustaining profitable growth. We generated 19 percent premium revenue growth that was well balanced between organic growth and bolt-on acquisitions. Our earnings per share fell short of our 2024 guidance primarily due to higher than expected medical costs in our Medicaid and Medicare segments. Our pre-tax margin, however, was squarely within our long- term target range. During the year, we closed the acquisition of the Bright Health California Medicare business, and launched new Medicaid health plans in Nebraska, New Mexico, and Texas. We also agreed to acquire the ConnectiCare business from Emblem Health, which we closed in early 2025.

“We continue to

execute our strategy for sustaining

profitable growth.”

2024 was also a highly successful year on the Medicaid and Medicare Duals procurement front. In Medicaid, we successfully reprocured contracts in Florida, Michigan, and Wisconsin, and were awarded a new contract in Georgia – a new state in our portfolio. In our Medicare Duals integrated product business – a strategic focus for us – we successfully procured new contracts in Idaho, Massachusetts, Michigan, and Ohio. Collectively, these acquisitions and organic revenue growth achievements represent approximately $10 billion of annual premium revenue when all these contracts are in force.

I am extremely pleased with the momentum we created through our operational and financial successes during 2024. We continue to see sustainable, profitable growth opportunities to expand our pure-play government managed care franchise into 2025 and beyond.

Thank you for your ongoing support and interest in our Company. We are most grateful for the confidence you express in our team and the Company’s mission, as demonstrated by your continued ownership.

Sincerely,

Joseph M. Zubretsky

President and Chief Executive Officer

Reconciliation of GAAP to Adjusted Net Income perDiluted Share

2024

2023

2022

2021

2020

Net Income

$ 20.42

$ 18.77

$ 13.55

$ 11.25

$ 11.23

Adjustments:

Amortization of intangible assets

1.43

1.47

1.32

0.83

0.26

Acquisition-related expenses (1)

1.14

0.12

0.83

1.59

0.37

Impairment (2)

-

-

3.56

-

-

Loss (gain) of debt repayment

-

-

-

0.43

0.26

Marketplace risk corridor judgment

-

-

-

-

(2.14)

Other (3)

0.28

1.17

-

0.16

0.51

Subtotal, adjustments

2.85

2.76

5.71

3.01

(0.74)

Income tax effect

(0.62)

(0.65)

(1.34)

(0.72)

0.18

Adjustments, net of tax effect

2.23

2.11

4.37

2.29

(0.56)

Adjusted net income

$ 22.65

$ 20.88

$ 17.92

$ 13.54

$ 10.67
  1. Reflectsnon-recurring costs associated with acquisitions, including various transaction and certain integration costs.
  2. Impairment attributable to the Company's plan to reduce its leased real estate footprint.
  3. 2024 includesnon-recurring litigation. 2023 includes a non-recurring credit loss on 2022 Marketplace risk adjustment receivables due to the insolvency of an issuer in the Texas risk pool, non-recurring litigation costs and one-time termination benefits. 2022 includes certain non-recurring costs associated with gain on lease termination and disposal of fixed assets. 2021 includes change in premium deficiency reserve, loss on sale of property, and restructuring costs. 2020 includes charitable contribution, premium deficiency reserves, and restructuring costs.

*#)())(

(*')(#-#$""(($#

,1C89>7D?>

?B=

"1B;$>5

##*!'%$')%*'(*#))$()$#$'4$)(*')(-# )$

$')(!.'#"'

?B

)'#()$# '%$') %*'(*#) )$ ()$# $' 4 $ ) (*')( -#)$$'))'#()$#%'$'$"00000000)$00000000

?==9CC9?>9<5#E=25B

"$!#!)'#

H13D>1=5?6B579CDB1>D1CC@53969549>9DC381BD5B

5<1G1B5

(D1D5?B?D85B:EB9C493D9?>?6

' ( =@<?I5B

9>3?B@?B1D9?>?B?B71>9J1D9?>

45>D96931D9?>#?

$351>71D5(E9D5!?>751381<96?B>91

33A4BB>5?A8=28?0;4G42DC8E4>55824B/8?>34

(468BCA0=CKBC4;4?7>=4=D<14A8=2;D38=60A402>34

(53EB9D95CB579CD5B54@EBCE1>DD?(53D9?>2?6D853D

)9D<5?6138<1CC

)B149>7(I=2?<>

#1=5?6138H381>75?>,8938'579CD5B54

?==?>(D?3; %1B+1<>

"$

#5G.?B;(D?3;H381>75

(53EB9D95CB579CD5B54@EBCE1>DD?(53D9?>7?6D853D

#?>5

$F<_a3b_9l3d_3a_q3b_40_3d_3b_ce9jca>L@=J=?AKLJ9FLAK9O=DDCFGOFK=9KGF=<_akkm3d_j9k3c_3d_>AF=<_af-md3d_g>L@=.=;MJALA=K ;L4=K)G $F<_a3b_9l3d_3a_q3b_40_3d_3b_ce9jca>L@=J=?AKLJ9FLAKFGLJ=IMAJ=<lg>AD=J=HGJLKHMJKM9FLLG.=;LAGFGJ.=;LAGF<>G>L@= ;L4=K)G $F<_a3b_9l3d_3a_q3b_40_3d_3b_ce9jco40_3d_l40_3d_jl40_3d_j3d_3f_aklj9fl _40_9k="">AD=<9DDJ=HGJLKJ=IMAJ=<_lg3a_3d_>AD=<:Q.=;LAGFGJ< G> L@=.=;MJALA=K P;@9F?=;LG><><_af3f_egfl40_kgj>GJKM;@K@GJL=JH=JAG<_l40_9ll40_3d_j3d_3f_aklj9fl o9k="" j="IMAJ=<" lg="">AD= KM;@ J=HGJLK 9F<> @9K :==F KM:B=;L LG KM;@ >ADAF? J=IMAJ=E=FLK >GJ L@= H9KL 4=K)G $F<><_hmjkm9fllg-md3d_g>-=?MD9LAGF./TG>L@AK;@9HL=J <><_af3f_egfl40_kgj>GJ KM;@K@GJL=JH=JAG<><_lgkm3a_ealkm3b_40_>AD=K 4=K)G $F<_a3b_9l3d_3a_q3b_40_3d_3b_ce9jco40_3d_l40_3d_jl40_3d_j3d_3f_aklj9flak9d9j3f_3d_93b_3b_3d_d3d_j9l3d_3c_>AD=J9F9;;=D=J9L=<>AD=J9FGF9;;=D=J9L=<>>AD=J9KE9DD=JJ=HGJLAF?;GEH9FQGJ9F=E=J?AF??JGOL@;GEH9FQ.==L@=<=>AFALAGFKG>XD9J?=9;;=D=J9L=<>AD=JY X9;;=D=J9L=<>AD=JYXKE9DD=JJ=HGJLAF?;GEH9FQY9F<_x3d_e3d_j3f_af3f_3f_jgol40_3b_geh9fqyaf-md3d_3a_g>L@= P;@9F?=;L

'9J?=9;;=D=J9L=<>AD=J ;;=D=J9L=<>AD=J )GF9;;=D=J9L=<>AD=J .E9DD=JJ=HGJLAF?;GEH9FQ

E=J?AF??JGOL@;GEH9FQ

$> 9F =E=J?AF? ?JGOL@ ;GEH9FQ AF<_a3b_9l3d_ _3a_q="" _3b_40_=";C" e9jc="" a=""> L@= J=?AKLJ9FL @9K =D=;L=<>FGL LG MK= L@= =PL=F<=< LJ9FKALAGFH=JAG<>GJ;GEHDQAF?OAL@9FQF=OGJJ=NAK=<>AF9F;A9D9;;GMFLAF?KL9F<9J<><_hmjkm9fllg.3d_3b_lagf 9="" g="">L@= P;@9F?=;L $F<_a3b_9l3d_3a_q3b_40_3d_3b_ce9jco40_3d_l40_3d_jl40_3d_j3d_3f_aklj9fl40_9k>AD=<9J=HGJLGF9F<9LL=KL9LAGFLGALKE9F9?=E=FLWK9KK=KKE=FL G>L@==>>=;LAN=F=KKG>ALKAFL=JF9D;GFLJGDGN=J>AF9F;A9DJ=HGJLAF?MF<=J.=;LAGF: G>L@=.9J:9F=K*PD=Q;L 0.: :QL@=J=?AKL=J=<_hm3a_da3b_93b_3b_gmflaf3f_>AJEL@9LHJ=H9J=<><><> $> K=;MJALA=K 9J= J=?AKL=J=<>HMJKM9FL LG .=;LAGF : G> L@= ;L AF<_a3b_9l3d_ _3a_q="" _3b_40_=";C" e9jc="" _o40_="L@=J" _l40_="">AF9F;A9D KL9L=E=FLK G> L@= J=?AKLJ9FL AF;DM<=< AF L@= >ADAF? J=>D=;L L@= ;GJJ=;LAGF G> 9F =JJGJ LG HJ=NAGMKDQ AKKM=<>>AF9F;A9D KL9L=E=FLK $F<_a3b_9l3d_3a_q3b_40_3d_3b_ce9jco40_3d_l40_3d_j9fqg>L@GK==JJGJ;GJJ=;LAGFK9J=J=KL9L=E=FLKL@9LJ=IMAJ=<9J=;GN=JQ9F9DQKAKG> AF;=FLAN=:9K=<>;GEH=FK9LAGF J=;=AN=<>:Q 9FQ G> L@= J=?AKLJ9FLWK =P=;MLAN= G>>A;=JK $F<_a3b_9l3d_ _3a_q="" _3b_40_=";C" e9jc="" _o40_="L@=J" _l40_="J=?AKLJ9FL" ak="" 9="" _k40_="DD" _3b_geh9fq="" 9k="" _3c_="">AF=<>AF -MD= : G> L@= ;L 4=K)G

/@=9??J=?9L=E9JC=LN9DM=G>GEEGF.LG;C@=D<:QFGF9>>ADA9L=KG>L@=J=?AKLJ9FL9KG>%MF=L@=D9KL

:MKAF=KK<9QG>GMJEGKLJ=;=FLDQ;GEHD=L=<_k3d_3b_gf3c_>AK;9DIM9JL=JO9K9HHJGPAE9L=DQ:ADDAGF:9K=<_mhgfl40_3d_ _3b_dgkaf3f_hja3b_="">GJK@9J=KG>L@=J=?AKLJ9FLWKGEEGF .LG;C9KJ=HGJL=<:QL@=)=O4GJC .LG;C P;@9F?= $F;GF %MF=

KG>!=:JM9JQ9HHJGPAE9L=DQEADDAGFK@9J=KG>L@=J=?AKLJ9FLWKGEEGF.LG;CH9JN9DM=H=J

K@9J=O=J=GMLKL9F<>

$*"#)(#$'%$').''#

+GJLAGFK G> L@= J=?AKLJ9FLWK +JGPQ .L9L=E=FL >GJ L@= FFM9D (==LAF? G> .LG;C@GD<=JK 9J= AF;GJHGJ9L=< :Q J=>=J=F;=AFLG+9JL$$$G>L@AKFFM9D-=HGJLGF!GJE&LGL@==PL=FL</lg>

"$!#!)'# $'"

)!$$#)#)(

%1BD

D5=#E=25B

MKAF=KK

-AKC!9;LGJK

0FJ=KGDN=<.L9>>GEE=FLK

Q:=JK=;MJALQ

+JGH=JLA=K

'=?9D+JG;==<>

(AF=.9>=LQAK;DGKMJ=K

%1BD

(9JC=L>GJ-=?AKLJ9FLWKGEEGF IMALQ-=D9L=<.LG;C@GD<=J(9LL=JK9F<$KKM=J+MJ;@9K=KG> IMALQ

.=;MJALA=K

6-=K=JN=<7

(9F9?=E=FLWKAK;MKKAGF9F<f9dqkakg>!AF9F;A9DGF<_alagf9f3c_-3d_kmdlkg>*H=J9LAGFK</f9dqkakg>

,M9FLAL9LAN=9F<,M9DAL9LAN=AK;DGKMJ=K:GML(9JC=L-AKC

!AF9F;A9D.L9L=E=FLK9F<.MHHD=E=FL9JQ9L9
@9F?=KAF9F<>
GFLJGDK9F

*L@=J$F>GJE9LAGF

AK;DGKMJ=-=?9J<><>

%1BD

AJ=;LGJK P=;MLAN=*>>A;=JK9F<>

P=;MLAN=GEH=FK9LAGF

.=;MJALQ*OF=JK@AHG>=JL9AF=F=>A;A9D*OF=JK9F<(9F9?=E=FL9F<-=D9L=<.LG;C@GD<=J(9LL=JK
=JL9AF-=D9LAGFK@AHK9F

+JAF;AH9D;;GMFL9FL!==K9F<.=JNA;=K

%1BD+
P@A:ALK9F

!GJE&.MEE9JQ

(&- 341$2

%175

)GLHHDA;9:D=

)GLHHDA;9:D=

)GLHHDA;9:D=

)GLHHDA;9:D=

)GLHHDA;9:D=

)GLHHDA;9:D=

This page was intentionally left blank

$',' !$$ #())"#)(

/@AKFFM9D-=HGJLGF!GJE&L@AKX!GJE&Y ;GFL9AFK>GJO9J<><_km3b_40_>GJO9J<>DGGCAF?KL9L=E=FLKLG:=;GN=J=<_mf3c_3d_jl40_3d_k9>=@9J:GJHJGNAKAGFK>GJ>GJO9J<><> .=;LAGFG>L@=.=;MJALA=K;LG>GJ.=;MJALA=K;L9F<.=;LAGF G>L@=.=;MJALA=K P;@9F?=;LG> GJ.=;MJALA=K P;@9F?=;L(9FQG>L@=>GJO9J<><><f9dqkakg>!AF9F;A9DGF<_alagf9f3c_-3d_kmdlkg>*H=J9LAGFKY!GJO9J<_dggcaf3f_ kl9l="E=FLKHJGNA<=;MJJ=FL=PH=;L9LAGFKG">>MLMJ==N=FLK:9K=<_gf3b_3d_jl9af9kkmehlagfk9f3c_9ddkl9l3d_e3d_flkgl40_3d_j _l40_9fkl9l="E=FLKG">@AKLGJA;9D>9;L;GFL9AF=<_afl40_ak21_gje26_e9q3a_3d_>GJO9J<_dggcaf3f_kl9l3d_e3d_flk24_fkge3d_3b_9k3d_k _qgm3b_9fa3c_="FLA">Q>GJO9J<><_kkm3b_40_9kx3f_ma3c_9f3b_3d_yx>MLMJ=YX9FLA;AH9L=KYX:=DA=N=KY X=E:=<<=<><><><><_yx3b_9fy _xe9qygjl40_="F=?9LAN=G">L@=K=L=JEKGJGL@=JKAEAD9J=PHJ=KKAGFK!GJO9J<><><_af3f_gmj>MLMJ=J=KMDLKG>GH=J9LAGFK9F<>AF9F;A9D HGKALAGFAF<><><><_gmjg3a_b3d_3b_lan3d_k>GJ>MLMJ= GH=J9LAGFK-=9<=JK9J=;9MLAGF=<><_m3d_j3d_da9f3b_3d_gf9fq>GJO9J<_dggcaf3f_kl9l3d_e3d_flk9kl40_3d_>MLMJ=AK AF@=J=FLDQMFHJ=<_a3b_l93a_d3d_ _40_mk="">GJO9J<_dggcaf3f_kl9l3d_e3d_flk9j3d_fgl3f_m9j9fl3d_3d_kg>>MLMJ=H=J>GJE9F;=9F>=JKA?FA>A;9FLDQ<><><> /@GK=CFGOFJAKCK9F<><><_lgl40_3d_>GDDGOAF?

C748<?;4<4=C0C8>=8=>5#4382083A0C4039DBC<4=CB0=3D?30C4BC70C0A4=>C2><<4=BDA0C4F8C7C74

2DAA4=C<43820;2>BCCA4=3B8=>DABC0C4B0=3C74740;C702D8CH;4E4;B>5>DA<4<14AB

N

5434A0;>ABC0C4;468B;0C8E4>AA46D;0C>AH270=64BC>C74#4382083#43820A4>A#0A:4C?;024?A>6A0<>

C>C74270=648=?A4B834=C80;03<8=8BCA0C8>=B8=2;D38=65D=38=6270=64BC>C745434A0;<0C278=6?4A24=C064

1;>2:6A0=CB>A?4A20?8C020?BF>A:A4@D8A4<4=CBC74=>= A4=4F0;>5#0A:4C?;024BD1B8384B?A>E834AC0G4B

>A0<4=3<4=CB>5C7455>A301;40A42CLM

N

1D364C?A4BBDA4B>=BC0C46>E4A=<4=CB0=3BC0C4BK455>ACBC>A43D24A0C4B>A;8<8CA0C48=2A40B4B

Z

4E>;E8=6#0A:4C?;0243H=0<82B8=2;D38=68BBD4B8<?02C8=64=A>;;<4=CB?4280;4=A>;;<4=C?4A8>3B<4<14A
27>824?A4<8D<_bd1b8384ba8b3a_039dbc3c_43d_c4bc83c_0c4b03d_3a4bd3b_cb23_0a3a_4c3f_3b_0243f_3b_03d_83d_b>;E4=284B>A

A4248E4AB78?B0=3C74?>C4=C80;5>A38B?A>?>AC8>=0C44=A>;;<4=C>578674A02D8CH<4<14AB

Z

C74BD224BB>5>DA455>ACBC>A4C08=4G8BC8=6>A0F0A3436>E4A=<4=C2>=CA02CBC74BD224BB>5>DA183

BD1<8BB8>=B8=A4B?>=B4C>A4@D4BCB5>A?A>?>B0;0=3>DA018;8CHC>834=C85H<4A64A0=302@D8B8C8>=C0A64CBC>

BD??>AC>DA2>=C8=D436A>FC7>E4AC8<40C?A>942C43;4E4;B

Z

C74BD224BB>5C74B20;8=6D?>5>DA>?4A0C8>=B8==4FBC0C4B8=2>==42C8>=F8C7A4@D4BC5>A?A>?>B0;F8=B0=3

C74B0C8B502C8>=>50;;A4038=4BBA4E84FA4@D8A4<4=CBD=34AC74=4F#43820832>=CA02CB

N

>DA018;8CHC>8=C46A0C4>DA02@D8B8C8>=B0=3A40;8I414=458CB0B?A>942C43

Z

 BD1B4@D4=C039DBC<4=CBC>A4?>AC43?A4<8D<_a4e43d_d410b43d3f_>=BD1B4@D4=C34E4;>?<4=CB>A=4F

8=5>A<0C8>=8=2;D38=6A4CA>02C8E4#4382083A0C4039DBC<4=CB8=0BC0C4>A270=64BC>4BC8<0C430<>D=CB?0H01;4

>AA4248E01;4A4;0C43C>#0A:4C?;024A8B:039DBC<4=C

Z

45542C8E4<0=064<4=C>5>DA<43820;2>BCB

Z

>DA018;8CHC>?A4382CF8C70A40B>=01;4346A44>5022DA02HDC8;8I0C8>=A0C4B

Z

 2H14A 0CC02:BA0=B><_f0a40cc023a_b>A>C74A?A8E02H>A30C0B42DA8CH8=2834=CB8=E>;E8=648C74A>DAB4;E4B>A>DA

2>=CA02C43E4=3>ABC70CA4BD;C8=0=8=03E4AC4=CD=0DC7>A8I4338B2;>BDA4>5?A>C42C438=5>A<0C8>=>A>?4A0C8>=0;

34;0HB0=3C744GC4=CC>F7827>DAF>A:8=68=0A4<>C4F>A:4=E8A>=<4=C74867C4=B>DA4G?>BDA4C>C74B4

A8B:B

Z

 C74018;8CHC><0=064>DA>?4A0C8>=B8=2;D38=6<08=C08=8=60=32A40C8=6034@D0C48=C4A=0;BHBC4<_b03d_32>=CA>;B

A4;0C8=6C>0DC7>A8I0C8>=B0??A>E0;B?A>E834A?0H<4=CB0=3C74>E4A0;;BD224BB>5>DA20A4<0=064<4=C

8=8C80C8E4B

N

>?4A0C8>=0;8<?A>E4<4=CB4558284=284B0=32>BCB0E8=6BC70C0A4;4BBC70=0=C828?0C43>AC70CA4BD;C8=

D=5>A4B44=2>=B4@D4=24B5A><>DA8=E4BC<4=CB8=0AC858280;8=C4;;864=24L M03<8=8BCA0C8E4C>>;B0=3

8=8C80C8E4B

N

C748<?02C>5>DAF>A:8=68=0A4<>C4F>A:4=E8A>=<4=C

Z

 >DAA4248?C>5034@D0C4?A4<8D<a0c4bc>BD??>AC8=2A40B8=6?70A<02H2>BCB8=2;D38=62>BCB0BB>280C43F8C7</a0c4bc>
B?4280;CH3AD6B0=32>BCBA4BD;C8=65A><5>A<_d3b_0ah2703d_64bc70c03b_3b_>FC74>?C8>=>578674A ?A8243=>= 64=4A82

3AD6B

Z

C748=C4A?A4C0C8>=8<?;4<4=C0C8>=0=34BC8<0C4B>50<>D=CB>F435>A5434A0;>ABC0C4<43820;2>BC4G?4=38CDA4
5;>>AB03<8=8BCA0C8E42>BC0=3?A>58C248;8=6B?A4<8D<_bc0183b_8i0c8>=?A>6A0<_b3f_a>58C B70A8=60AA0=64

A8B:039DBC<4=C?A>E8B8>=B0=3A4@D8A4<4=CB

</f9dqkakg>

(GDAF9#=9DL@;9J=$F;!GJE&S

Z

 C748=C4A?A4C0C8>=0=38<?;4<4=C0C8>=>50C A8B:?A4<8D<_ad3b_4b03d_3bc0c42>=CA02C?4A5>A

A460A38=6C7402784E4<4=C>524AC08=@D0;8CH<40BDA4B0=3>DA018;8CHC>A42>6=8I4A4E4=D40<>D=CB

0BB>280C43C74A4F8C7

Z

 C74CA0=B8C8>=>5#43820A4 #4382083?8;>C?A>6A0<_b83d_03b_85>A=80 ;;8=>8B#827860=%78>)>DC70A>;8=00=3

*4G0BB4AE8=6C7>B43D0;;H4;8681;45>A1>C7#43820A40=3#4382083C748=2A40B8=68=C46A0C8>=>5#43820A40=3

#4382083?A>6A0<<0C820=32><?;80=24A4@D8A4<4=CB0=3C744GC4=B8>=>A8=2>A?>A0C8>=>55434A0;#43820A4

A4@D8A4<4=CB34E4;>?431HC744=C4AB5>A#43820A40=3#4382083)4AE824BL#)M8=C>BC0C4 03<8=8BC4A43

#4382083?A>6A0<>

N

C74022DA0C44BC8<0C8>=>58=2DAA431DC=>CA4?>AC43>A?083<43820;2>BCB02A>BB>DA740;C7?;0=B

Z

270=64B8=>DA0==D0;45542C8E4C0GA0C43D4C>5434A0;0=3>ABC0C4;468B;0C8>=>A270=64B8=>DA<8G>540A=8=6B

0=3>C74A502C>AB

Z

C744558284=C0=345542C8E4>?4A0C8>=B>5C74E4=3>AB>=F7><>DA1DB8=4BBA4;84B

Z

2><?;820C8>=B<4<14A2>=5DB8>=>A4=A>;;<4=C102:;>6BA4;0C43C>C74A4=4F0;>5#43820832>E4A064

Z

5A0D3F0BC40=301DB4<0CC4AB6>E4A=<4=C0D38CBA4E84FB>A8=E4BC860C8>=B2><<4=C;4CC4AB0=30=H58=4
B0=2C8>=4=A>;;<4=C5A44I43410A<4=C2>AA42C8E402C8>=?;0=<>=8C>A8=6?A>6A0<>A?A4<8D<a42>E4AHC70C</a42>

<0HA4BD;CC74A45A><

Z

C74BD224BB>5>DA?A>E834AB8=2;D38=634;460C43?A>E834ABC74034@D02H>5>DA?A>E834A=4CF>A:BC74

BD224BB5D;<08=C4=0=24>5A4;0C8>=BF8C7>DA?A>E834AB0=3C74?>C4=C80;;>BB>5?A>E834AB

Z

0??A>E0;1HBC0C4A46D;0C>AB>538E834=3B0=338BCA81DC8>=B1H>DA740;C7?;0=BD1B8380A84B

Z

 78673>;;0A2;08<_ba43b_0c43c>20C0BCA>?7828;;=4BB

Z

C7450E>A01;4A4B>;DC8>=>5;8C860C8>=0A18CA0C8>=>A03<8=8BCA0C8E4?A>24438=6B

Z

C746A40C4AB20;40=3A4E4=D4B>5>DA740;C7?;0=B8=0;85>A=80$4F.>A:*4G0B0=3-0B78=6C>=0=3A8B:B

A4;0C43C>C742>=24=CA0C8>=>5>DA1DB8=4BB8=C7>B4BC0C4B

Z

C74508;DA4C>2><?;HF8C7C7458=0=280;>A>C74A2>E4=0=CB8=C742A438C06A44<4=C6>E4A=8=6>DAA4E>;E8=62A438C

5028;8CH>AC748=34=CDA4B6>E4A=8=6>DA>DCBC0=38=6B4=8>A=>C4B

Z

 C740E08;018;8CH>5034@D0C458=0=28=6>=0224?C01;4C4A<bc>5D=30=320?8C0;8I4>DA4G?0=B8>=0=36A>FC70=3</bc>

<44C>DA64=4A0;;8@D838CH=443B

Z

C74508;DA4>50BC0C48=F7827F4>?4A0C4C>A4=4F8CB5434A0;#4382083F08E4A

Z

270=64B64=4A0;;H05542C8=6C74<0=064320A48=3DBCAH8=2;D38=60=H=4F5434A0;>ABC0C4;468B;0C8>=C70C

8<?02CBC741DB8=4BBB?0248=F7827F4>?4A0C4

Z

8=2A40B4B8=6>E4A=<4=CBDA270A64BC0G4B0=30BB4BB<4=CB

Z

C748<?02C>58=5;0C8>=>=>DA<43820;2>BCB0=3C742>BC>5A458=0=28=6>DA>DCBC0=38=68=341C43=4BB

Z

C74D=4G?42C43;>BB>5C74;4034AB78?>5>=4>A<>A4>5>DAB4=8>A4G42DC8E4B

Z

8=2A40B8=62><?4C8C8>=0=32>=B>;830C8>=8=C74#4382083>A64=4A0;740;C720A4B42C>A0=3

N

C74>C74AA8B:502C>AB834=C858438=C74B42C8>=>5C78B>A<>!C8C;43L(8B:02C>AB M

9;@G>L@=L=JEKX(GDAF9#=9DL@;9J=$F;YX(GDAF9#=9DL@;9J=YXGEH9FQYXO=YXGMJY9F<_xmky9kmk3d_3c_40_3d_j3d_af j="">=JK;GDD=;LAN=DQLG(GDAF9#=9DL@;9J=$F;9F<><><>GJO9J<><mhgfaf>GJE9LAGF9N9AD9:D=LGMK9KG>L@=<9L=G>L@AK!GJE &9F<_o40_ad3d_o3d_3a_3d_da3d_n3d_km3b_40_af>GJE9LAGF>GJEK9J=9KGF9:D=:9KAK>GJKM;@KL9L=E=FLKKM;@AF>GJE9LAGFE9Q :=DAEAL=<><><><><><_m3b_l3d_3c_9f3d_p40_9mklan3d_ afimajqaflggjj="NA=OG">9DDHGL=FLA9DDQ9N9AD9:D=J=D=N9FLAF>GJE9LAGF2=IM9DA>Q9DDG>GMJ>GJO9J<_dggcaf3f_ kl9l="E=FLK:QL@=K=;9MLAGF9JQKL9L=E=FLK/@=K=">GJO9J<_dggcaf3f_kl9l3d_e3d_flkkh3d_9cgfdq9kg>L@=<9L=G>L@AK !GJE&/@=GEH9FQ9KKME=KFGG:DA?9LAGFLGJ=NAK=GJMH<9L=9FQ>GJO9J<_dggcaf3f_kl9l3d_e3d_flk>GJ9FQ J=9KGF=P;=HL9KJ=IMAJ=</mhgfaf>

(GDAF9#=9DL@;9J=$F;!GJE&S

Disclaimer

Molina Healthcare Inc. published this content on March 18, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 18, 2025 at 04:08:37.550.

Advisor News

More Advisor News

Annuity News

Sponsor
More Annuity News

Health/Employee Benefits News

More Health/Employee Benefits News

Life Insurance News

Sponsor
More Life Insurance News